Parmax Pharma Fair Value
Parmax Pharma (PARMAX) average fair value is ₹158.26 across 1 valuation models — Price-to-Sales Valuation, vs a current market price of ₹39.96 (+296.05%), fair value range ₹158.26–₹158.26. For live price and a broader fundamental view, visit PARMAX share price.
Fair Value Analysis Export
PARMAX Fair Value vs Current Price — Valuation Summary
PARMAX average fair value, fair value range, price gap and valuation status across 1 models: Price-to-Sales Valuation. See PARMAX price to book ratio to compare market price against book value per share.
Price-to-Sales Valuation
PARMAX Fair Value Analysis — Data Sources & Coverage
Parmax Pharma financial data sources, valuation methods applied and sector benchmarks used. Also explore Parmax Pharma share price performance to track price trends across different timeframes.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
PARMAX vs Healthcare Sector Peers — P/E, P/B & Market Cap
Parmax Pharma P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Accretion Pharmaceuticals | ACCPL | 13.72 | 2.43 | ₹131 |
| Par Drugs & Chemical | PAR | 8.67 | 1.01 | ₹111 |
| Jeena Sikho Lifecare | JSLL | 40.02 | 22.33 | ₹7,891 |
| Auro Laboratories | AUROLAB | 91.49 | 3.91 | ₹165 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.